Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 3
1955 2
1968 1
1976 1
1977 2
1991 1
1992 1
1995 1
1998 1
1999 1
2000 1
2002 2
2003 3
2004 2
2005 3
2006 5
2007 2
2008 3
2009 3
2010 2
2011 2
2012 2
2013 3
2014 2
2015 4
2016 11
2017 5
2018 11
2019 13
2020 14
2021 14
2022 12
2023 10
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Results by year

Filters applied: . Clear all
Page 1
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Kelley RK, et al. Among authors: rangel jdg. Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4. Lancet Oncol. 2022. PMID: 35798016 Free article. Clinical Trial.
Engaging cultural humility diffractively.
Crath R, Rangel JC. Crath R, et al. Among authors: rangel jc. J Eval Clin Pract. 2021 Jun;27(3):554-561. doi: 10.1111/jep.13409. Epub 2020 Jun 11. J Eval Clin Pract. 2021. PMID: 32529738
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Chen L, Rangel JDG, Cil T, Li X, Cicin I, Shen Y, Liu Z, Ozyilkan O, Igor B, Chen J, Oleksandr K, Chen Z, Zhang H, Fu Z, Dong Q, Song S, Yu JC, Zhang L. Chen L, et al. Among authors: rangel jdg. Cancer Med. 2023 Nov;12(22):20847-20863. doi: 10.1002/cam4.6664. Epub 2023 Nov 7. Cancer Med. 2023. PMID: 37935428 Free PMC article. Clinical Trial.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Yau T, et al. Among authors: rangel jdg. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13. Lancet Gastroenterol Hepatol. 2024. PMID: 38364832 Clinical Trial.
Does plant diversity benefit agroecosystems? A synthetic review.
Letourneau DK, Armbrecht I, Rivera BS, Lerma JM, Carmona EJ, Daza MC, Escobar S, Galindo V, Gutiérrez C, López SD, Mejía JL, Rangel AM, Rangel JH, Rivera L, Saavedra CA, Torres AM, Trujillo AR. Letourneau DK, et al. Among authors: rangel jh. Ecol Appl. 2011 Jan;21(1):9-21. doi: 10.1890/09-2026.1. Ecol Appl. 2011. PMID: 21516884 Review.
141 results